Each year radiology vendors use the Radiological Society of North America (RSNA) meeting as a springboard to unveil ...
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the next-generation reusable cryoplasty inflation device.
Consumers from California, Colorado and Wisconsin filed a nationwide class action lawsuit against Fitbit Inc. alleging the company’s wrist-based “Charge HR” and “Surge” heart rate monitors do not and cannot consistently record accurate heart rates during the intense physical activity for which Fitbit expressly markets the devices.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
GE Healthcare announced that it has chosen Chicago as its global headquarters, effective early 2016.
Fujifilm VisualSonics Inc. announced CE mark for the Vevo MD, what the company calls the world’s first ultra-high frequency (UHF) clinical ultrasound system. The announcement marks Fujifilm VisualSonics’ expansion into the clinical market.
A new study published online in JACC: Cardiovascular Interventions reveals that delays in recognizing symptoms of heart attack patients and seeking treatment are associated with increased damage to the heart.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical trial will compare the MiStent SES sirolimus eluting absorbable polymer coronary stent system to Abbott’s Xience stent.
XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to continuous-flow ECLS (extracorporeal life support) in cardiogenic shock.
January 7, 2016 — Celyad announced Dec. 21 that the U.S. Food and Drug Administration (FDA) has authorized the company’s ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited release of its MicroCross Catheter, the latest addition to Roxwood Medical’s expanding product line. The MicroCross Catheter is U.S. Food and Drug Administration (FDA)-cleared and offered in two sizes (Micro14 and Micro18) for use in the coronary and peripheral vasculatures, providing enhanced guidewire support through challenging and tortuous anatomy.
Stroke is the third leading cause of death in the Western industrialized world, and according to the Centers for Disease Control (CDC), accounts for one of every 19 deaths in the United States each year. Over 80 percent of strokes are ischemic in nature, caused by clots and other obstructions in vessels that supply blood to the brain, and cardiac embolism accounts for approximately one-third of all cases of ischemic stroke. Echocardiography in general and transesophageal echocardiography in particular are essential for evaluation, diagnosis and management of stroke and systemic embolism. A new document, Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism, will appear in the January 2016 issue of the Journal of the American Society of Echocardiography (JASE) and provides the first set of guidelines from the American Society of Echocardiography (ASE) specific to this topic.
January 7, 2016 — Scientists have found that women who suffer unexplained heart failure towards the end of pregnancy or ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Corindus Vascular Robotics Inc. announced the launch of a CorPath robotic-assisted coronary intervention program at Massachusetts General Hospital (MGH) and the installation of its first CorPath System.
Clinical decision support (CDS) software has been discussed for years as a way to help clinicians follow best practice ...
A new study determined that the Watchman left atrial appendage closure device is more cost-effective than warfarin and non-warfarin oral anticoagulants (NOACs) for stroke reductions in non-valvular atrial fibrillation patients.